NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive’s Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health and Animal Health Applications

The filings are intended to position EL-22 and EL-32 as potential muscle-preservation platforms not only for large terrestrial markets, but also for the emerging medical requirements associated with sustained human presence in space